Eqis Capital Management Inc. lessened its position in Bristol-Myers Squibb Company (NYSE:BMY) by 25.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,495 shares of the biopharmaceutical company’s stock after selling 7,211 shares during the quarter. Eqis Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $1,198,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. raised its stake in shares of Bristol-Myers Squibb by 18.7% during the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after acquiring an additional 2,451,390 shares in the last quarter. Swiss National Bank boosted its stake in shares of Bristol-Myers Squibb by 27.2% in the 1st quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock valued at $322,020,000 after purchasing an additional 1,267,900 shares in the last quarter. State Street Corp boosted its stake in shares of Bristol-Myers Squibb by 1.8% in the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock valued at $3,746,446,000 after purchasing an additional 1,223,457 shares in the last quarter. NN Investment Partners Holdings N.V. boosted its stake in shares of Bristol-Myers Squibb by 103.1% in the 2nd quarter. NN Investment Partners Holdings N.V. now owns 1,581,454 shares of the biopharmaceutical company’s stock valued at $88,119,000 after purchasing an additional 802,931 shares in the last quarter. Finally, Karp Capital Management Corp purchased a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at $38,890,000. 68.88% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have weighed in on the stock. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $65.00 price target (up from $62.00) on shares of Bristol-Myers Squibb in a research note on Thursday, September 7th. Hilliard Lyons lowered shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price target for the company. in a research report on Tuesday, September 12th. Jefferies Group LLC reaffirmed a “buy” rating and set a $64.00 price objective on shares of Bristol-Myers Squibb in a research note on Monday, June 5th. Piper Jaffray Companies set a $60.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Thursday, July 27th. Finally, BMO Capital Markets reiterated a “sell” rating and issued a $49.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, September 4th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $62.17.

Bristol-Myers Squibb Company (NYSE:BMY) traded down 0.46% during mid-day trading on Tuesday, reaching $64.26. The company’s stock had a trading volume of 2,927,151 shares. The firm’s 50 day moving average is $60.77 and its 200-day moving average is $56.42. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $64.79. The stock has a market cap of $105.38 billion, a P/E ratio of 23.47 and a beta of 1.19.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. The company had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. Bristol-Myers Squibb’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.69 earnings per share. Equities analysts expect that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th will be issued a $0.39 dividend. The ex-dividend date is Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.42%. Bristol-Myers Squibb’s dividend payout ratio is presently 56.73%.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Theodore R. Samuels II purchased 6,000 shares of the stock in a transaction dated Wednesday, August 2nd. The stock was purchased at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the acquisition, the director now directly owns 18,000 shares in the company, valued at approximately $1,006,920. The disclosure for this purchase can be found here. Company insiders own 0.23% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/03/bristol-myers-squibb-company-bmy-shares-sold-by-eqis-capital-management-inc.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.